CN115066435B - 针对lilrb2的单域抗体 - Google Patents

针对lilrb2的单域抗体 Download PDF

Info

Publication number
CN115066435B
CN115066435B CN202080065196.6A CN202080065196A CN115066435B CN 115066435 B CN115066435 B CN 115066435B CN 202080065196 A CN202080065196 A CN 202080065196A CN 115066435 B CN115066435 B CN 115066435B
Authority
CN
China
Prior art keywords
amino acid
sdab
acid sequence
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080065196.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115066435A (zh
Inventor
玛丽亚·卢斯塔乌
莉丝·胡诺尔特
皮埃尔·兰格拉德-德莫延
朱利安·考马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invectes Ag
Original Assignee
Invectes Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectes Ag filed Critical Invectes Ag
Publication of CN115066435A publication Critical patent/CN115066435A/zh
Application granted granted Critical
Publication of CN115066435B publication Critical patent/CN115066435B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN202080065196.6A 2019-09-20 2020-09-18 针对lilrb2的单域抗体 Active CN115066435B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306148.8 2019-09-20
EP19306148 2019-09-20
PCT/EP2020/076198 WO2021053199A1 (en) 2019-09-20 2020-09-18 Single-domain antibodies directed against lilrb2

Publications (2)

Publication Number Publication Date
CN115066435A CN115066435A (zh) 2022-09-16
CN115066435B true CN115066435B (zh) 2025-05-02

Family

ID=68654426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080065196.6A Active CN115066435B (zh) 2019-09-20 2020-09-18 针对lilrb2的单域抗体

Country Status (11)

Country Link
US (1) US20230235050A1 (https=)
EP (1) EP4031572A1 (https=)
JP (1) JP7627687B2 (https=)
KR (1) KR20220128332A (https=)
CN (1) CN115066435B (https=)
AU (1) AU2020351274A1 (https=)
BR (1) BR112022004534A2 (https=)
CA (1) CA3154450A1 (https=)
IL (1) IL291506A (https=)
MX (1) MX2022003365A (https=)
WO (1) WO2021053199A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333127B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN115975029A (zh) * 2022-06-28 2023-04-18 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
CN119768432A (zh) * 2022-08-22 2025-04-04 德琪(杭州)生物有限公司 新颖的抗lilrb2抗体和其用途
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN116789825A (zh) * 2023-05-12 2023-09-22 南京师范大学 抗lilrb1/lilrb2的全人源单域抗体及其应用
CN116789826A (zh) * 2023-05-12 2023-09-22 南京师范大学 抗人lilrb2全人源单域抗体及其应用
CN119176874A (zh) * 2023-06-21 2024-12-24 康源博创生物科技(北京)有限公司 一种能够结合lilrb2的抗体或其抗原结合片段
CN119619509A (zh) * 2023-09-05 2025-03-14 中日友好医院(中日友好临床医学研究所) 一种结直肠癌治疗靶点和血清标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2687633A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2016111947A2 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA2977544C (en) * 2015-03-06 2023-12-19 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
EA202091540A1 (ru) * 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途

Also Published As

Publication number Publication date
CN115066435A (zh) 2022-09-16
BR112022004534A2 (pt) 2022-06-07
JP7627687B2 (ja) 2025-02-06
JP2022548764A (ja) 2022-11-21
CA3154450A1 (en) 2021-03-25
EP4031572A1 (en) 2022-07-27
WO2021053199A1 (en) 2021-03-25
AU2020351274A1 (en) 2022-05-05
US20230235050A1 (en) 2023-07-27
KR20220128332A (ko) 2022-09-20
IL291506A (en) 2022-05-01
MX2022003365A (es) 2022-08-22

Similar Documents

Publication Publication Date Title
CN115066435B (zh) 针对lilrb2的单域抗体
JP7842703B2 (ja) 抗Ｃｌａｕｄｉｎ１８．２抗体およびその使用
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
TW202144417A (zh) Ｐｖｒｉｇ結合蛋白及其醫藥用途
CN109988240B (zh) 抗gpc-3抗体及其用途
TWI902681B (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
JP5868176B2 (ja) 抗癌活性を有する抗体
TWI836070B (zh) 抗trop-2抗體、其抗原結合片段及其醫藥用途
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN117242092A (zh) Vegfa结合分子
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
TW202417496A (zh) 分離的抗原結合蛋白及其用途
CN114729013A (zh) 抗cd22抗体及其用途
CN117820466A (zh) 抗志贺毒素抗体及其应用
TW202413422A (zh) 抗體、其抗原結合片段及其藥物用途
KR20190135478A (ko) 항 gpr20 항체
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
EA046196B1 (ru) Однодоменные антитела, направленные против lilrb2
WO2011052753A1 (ja) Mansc1蛋白質に結合し、抗癌活性を有する抗体
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40076989A (en) Anti-cd22 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant